Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model

    Access Status
    Fulltext not available
    Authors
    Tan, M.
    Friedhuber, A.
    Dass, Crispin
    Date
    2013
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Tan, M. and Friedhuber, A. and Dass, C. 2013. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model. Journal of Pharmacy and Pharmacology. 65 (1): pp. 35-43.
    Source Title
    Journal of Pharmacy and Pharmacology
    DOI
    10.1111/j.2042-7158.2012.01572.x
    ISSN
    0022-3573
    School
    Victoria University
    URI
    http://hdl.handle.net/20.500.11937/49673
    Collection
    • Curtin Research Publications
    Abstract

    Objectives: Chitosan is a green (natural, abundant, biodegradable, biocompatible) biopolymer that can be formulated to encapsulate a variety of therapeutic compounds. This study aimed to investigate chitosan nanoparticles (NPs) as a means of improving delivery of the clinically used anti-cancer agent doxorubicin (Dox) and the preclinical lead compound Dz13 oligonucleotide together. Methods: A novel chitosan NP system encapsulating Dox and Dz13 was designed, biophysically characterised and tested in a clinically relevant model of the metastasising bone tumour, osteosarcoma (OS). Key findings: By careful alteration of the concentration of the individual components, a final formulation of Dz13-Dox NPs (DDNPs) was achieved, with high (>91%) loading of both compounds, which consisted of individual 50-nm particles forming aggregates as large as 500 nm, with a large positive ζ-potential. The DDNPs could be stored at various temperatures for a week without loss in activity but were prone to degradation in serum. DDNPs successfully inhibited OS tumour growth more effectively than treatment with NPs of Dz13 and Dox-chitosan, as well as Dox administered intraperitoneally. Apart from inhibiting tumour growth, DDNPs protected the affected bone from substantial destruction by aggressive tumour growth and reduced the incidence of metastasis to the lungs without causing adverse effects in mice. Conclusion: This NP is a promising formulation that could be useful for clinical management of OS.

    Related items

    Showing items related by title, author, creator and subject.

    • Stimulation of bone regeneration with pigment epithelium-derived factor microparticles: Evidence in silico, in vitro and in vivo
      Lee, P.; Martinez, Jorge; Dass, Crispin (2016)
      The occurrence of bone defects can be due to a variety of factors not limited to bone fractures and tumours. Most diseased bone is removed and the patient fitted with prosthetics, prior to use of certain factors such as ...
    • Anti-Tumour Effect of a Chitosan Delivery System for Doxorubicin
      Tan, M.; Choong, P.; Dass, Crispin (2010)
      Used against a variety of tumours, doxorubicin (DOX), causes multiple side-effects in patients, especially in high doses required to control tumour growth. A drug delivery system (DDS) was developed to deliver DOX. Through ...
    • A nanoparticulate system that enhances the efficacy of the tumoricide Dz13 when administered proximal to the lesion site
      Tan, M.; Dunstan, D.; Friedhuber, A.; Choong, P.; Dass, Crispin (2010)
      We demonstrate that Dz13, a DNA enzyme that cleaves c-Jun mRNA, and is capable of inhibiting cancer cell growth in vitro, can be encapsulated into chitosan nanoparticles. For optimisation of this chitosan-based formulation, ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.